Ep 88: Negative Adjuvant Doublet Studies (CM915, KV010, RELA098)

<p><strong>Melanoma Matters: Why Adjuvant Doublet Immunotherapy Fell Short</strong></p><p><br /></p><p>Hobbies - James wishes he was surfing more </p><p><br /></p><p>This episode breaks down three negative adjuvant melanoma trials testing combination immunotherapy against anti PD 1 monotherapy. The discussion focuses on why toxicity rises without clear efficacy gains, and what these results mean for adjuvant and neoadjuvant strategy going forward.</p><p><br /></p><p>James Larkin and Sapna Patel also dig into a bigger question: if combination therapy helps in metastatic disease, why does it seem to lose its edge in microscopic or adjuvant disease?</p><p><br /></p><p><strong>Key topics</strong></p><p>In this episode, the hosts review three adjuvant trials:</p><ul><li>CheckMate 915</li><li>Relativity 098</li><li>KeyVibe 010 </li></ul><p><br /></p><ul><li>The bottom line across all three studies is negative efficacy for combination therapy versus monotherapy in the adjuvant setting.</li><li>The conversation emphasizes toxicity and discontinuation as a major issue with combination arms, especially when patients stop early because of adverse effects rather than progression.</li><li>They revisit the CheckMate 915 dosing question, noting that the ipilimumab exposure in that study was much lower than the classic EORTC adjuvant regimen.</li><li>The hosts compare dosing intensity and cumulative dose across adjuvant and metastatic settings, including the idea that dose density may matter as much as total dose.</li></ul><p><br /></p><ul><li>The episode raises a larger strategic question for melanoma care:</li><ul><li>Should adjuvant therapy remain monotherapy?</li><li>Should neoadjuvant treatment replace some adjuvant use?</li><li>Should patients receive both?</li></ul></ul>